A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

Next Previous
Trial Profile

A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2018

At a glance

  • Drugs Axicabtagene ciloleucel (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Acronyms ZUMA-5
  • Sponsors Kite Pharma

    • Most Recent Events

    • 02 Aug 2017 According to a Kite Pharma media release, first patient in this trial has been dosed.
    • 08 May 2017 Status changed from not yet recruiting to recruiting, according to a Kite Pharma media release.
    • 03 Apr 2017 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top